Cymabay Therapeutics, Inc. (NASDAQ:CBAY) recently ticked higher on weak volume. About 0.41 million contracts were traded on 21-Nov-17 compared to daily average volume of 0.75 million shares. The first sale was made at $8.63 but later the stock became weaker, and closed with a gain of 0.93%. It was last traded at $8.71 apiece.Cymabay Therapeutics, Inc. (CBAY): Outperform Candidate With 58.78% Upside Potential
Cymabay Therapeutics, Inc. is maintained at an average outperform rating by 6 stock analysts, and there are at least 6.3% of shares outstanding that are currently legally short sold. The shares went up by 10.53% in value last month. Year-to-date it jumped 403.47%. Analysts are turning out to be more optimistic than before, with 6 of analysts who cover Cymabay Therapeutics, Inc. (NASDAQ:CBAY) advice adding it to buy candidate list. Wall Street experts also assign a $13.83 price target on Cymabay Therapeutics, Inc., pointing towards a 58.78% rally from current levels. The stock is trading for about -7.34% less than its 52-week high.CBAY Adds 4.31% In A Week
This company shares (CBAY) so far managed to recover 496.58% since collapsing to its 52-week low. Over a month, it has seen its stock price volatility to stay at 4.31% while shortening the period to a week, volatility was 5.75%. The share price has yet to cross its 20 days moving average, floating at a distance of -0.1% and sits 5.9% higher versus its 50 days moving average. When looking at the past five sessions, the stock returned 4.31% gains and is up by 53.86% compared with its 200-day moving average of $6.57. Also, Cymabay Therapeutics, Inc. (CBAY) needs to expand a 329.06% increase it experienced over the past twelve months.Regulus Therapeutics Inc. (NASDAQ:RGLS) Consensus Call At 2.7
As regular trading ended, Regulus Therapeutics Inc. (RGLS) stock brought in a -$0.02 drop to $0.88. The day started at a price of $0.9 but then traded as high as $0.9025 before giving part of the gains back. As for this week, analysts appear content to stick with their neutral outlook with the consensus call at 2.7. Regulus Therapeutics Inc. is given 1 buy-equivalent recommendations, 0 sells and 5 holds. The company shares sank -71.61% from their peak of $3.10 and now has a $93.48 million market value of equity.
RGLS’s mean recommendation on Reuter’s scale presents no change from 2.67 thirty days ago to 2.67 now, which indicates a hold consensus from the analyst community. They see Regulus Therapeutics Inc. (RGLS) price hitting a mean target of $1.88 a share, meaning the stock still has potential that could lift the price another 113.64% Also, the recent close suggests the stock is underpriced by 70.45% compared to the most bullish target.Regulus Therapeutics Inc. (RGLS) Returns -60.88% This Year
The company had seen its current volume reaching at 0.83 million shares in the last trade. That compares with the recent volume average of 0.73 million. At the close of regular trading, its last week’s stock price volatility was 9.56% which for the month reaches 8.44%. Regulus Therapeutics Inc. dipped to as low as $0.8553 throughout the day and has returned -60.88% in this year. At one point in the past year, the shares traded as low as $0.79 but has recovered 10.87% since then.